Category Archives: Cancer Therapies

Oncotarget Publishes Potential Breakthrough Research On Breast Cancer Therapy

Breast cancer is one of the most aggressive forms of the disease. Recently, Oncotarget published a report which details a potential therapy for aggressive breast cancer cells. The research could potentially lead to a new and effective way to tackle breast cancer in millions of patients. Follow Oncotarget on Twitter.

The research report identifies a hormone therapy that can be especially effective against breast cancer if that therapy can express estrogen receptor beta. The report further identified several other molecules that should be investigated in the treatment of breast cancer. The entire report was featured in a recent cover story in the biomedical journal Oncotarget.

Breast cancer cell receptors for the sex hormone estrogen as well as progesterone can allow for the uncontrolled growth of the cells. A much more aggressive form of breast cancer known as triple-negative breast cancer can occur when there are no receptor proteins that bind to estrogen and progesterone. This type of cancer is resistant to hormone therapy and usually leads to cancer spreading to other parts of the body. Watch this video on Youtube.

Researchers found that the growth of the aggressive triple-negative breast does not have estrogen receptor alpha. Therefore, breast cancer can be slowed down significantly if the hormone therapy expresses estrogen receptor beta. This type of therapy was tested on a mouse model and was found to significantly stop tumor growth. In some cases, the cancerous mouse model was shown to go into tumor regression.

While further research needs to be done on estrogen receptor beta, the promising results from the mouse model have some researchers hopeful. Next steps will most likely include testing on human subjects before wider acceptance of the therapy.

Oncotarget is a biomedical journal published twice a week. The peer-reviewed publication covers Oncology as well as Microbiology, Autophagy, Pathology, Aging, as well as Chromosomes. Published by Rapamycin Press, Oncotarget is one of the most respected medical journals for cancer scientists and researchers.

Read more:

All About Entrepreneur Eric Lefkofsky

Eric Lefkofsky is one of the most successful entrepreneurs in America today. As one of the co-founders of Groupon, he has made a big impact in a number of industries. Today, Lefkofsky is CEO of Tempus. This startup has the ambitious goal of curing cancer. It’s a challenge not many people would want to take on. But Eric Lefkofsky has never shied away from a challenge.

Lefkofsky is a graduate of the University of Michigan, and the University of Michigan Law School. This is an unusual background for someone at the helm of a healthcare and technology company. However, Lefkofsky believes he has identified some key weaknesses in today’s standard cancer treatments and more information click here.

The first issue is that every patient is unique. From DNA to environmental factors such as diet, each patient will have nuances differentiate their case from others. Likewise, every tumor is also unique. By identifying the building blocks of each tumor, and measuring its growth rate, highly targeted treatments could be developed and learn more about Eric.

The second issue is that providers are only human. Even with the best of intuition and intent, there is only so much a doctor can do. With better data, they can recommend better treatments. Tempus processes reams of data that normally be impossible for humans to get through. By digesting a large quantity of data, Tempus gives medical providers an analytical tool to do their job more effectively and Eric’s lacrosse camp.

With personalized information, Eric Lefkofsky and the rest of the Tempus team hope to revolutionize cancer treatment. By collecting and tracking individual tumors, the hope is that survival rates will increase. And eventually, trends will emerge that could lead to a cure for cancer and his Facebook.

Eric Lefkofsky’s newest venture truly has the potential to change the world. It marries his keen business mind with his drive to make the world a better place. In addition to his career as an entrepreneur, Lefkofsky is always finding ways to give back to his community. For example, he serves as a Trustee for Lurie Children’s Hospital of Chicago, Steppenwolf Theatre Company and other worthy non-profit organizations.

Clay Siegall: A Legend in Cancer Therapies

Clay Siegall founded Seattle Genetics in 1998. The Company is a Bio-Tech firm that deals with targeted therapies for diseases that have not seen any improvements in the past years.

Clay is the C.E.O of the Seattle Genetics and has led the Company to achieve great success. He led the company to develop its first antibody conjugate. This was the first FDA approved drug.

Seattle Genetics has also created 20 drugs with renowned drug manufacturers. Seattle Genetics has grown to become a force of nature in the Cancer industry. Siegall has positioned the Company to become a voice of authority in the 21st century.

Clay Siegall attended the University of Maryland where he graduated with a Bachelor of Science in Zoology. He later received a Ph.D. in Genetics from the University of Washington.

From a young age, Clay has been interested in Medicine and the technology to overcome diseases. In an interview, Clay said that he developed an interest in Cancer after he saw a family member go through a brutal experience with cancer.

While money was a great motivation for him pursuing launching his Company, Clay said he wanted to create an alternative therapy to alleviate the pain of cancer and chemotherapy.

The Company raises its money from the drugs that they have developed. Seattle also generates revenue from the partnerships and licenses of their technologies. According to Clay, the company became successful and profitable after ten years of in the industry. When the Company was launched, Clay managed to get $675 million through private and public finances.

Unlike most businesses, Seattle uses a unique marketing strategy to promote their services. The team spends a significant amount of time to negotiate contracts. They have also gained a great legal team.

Before launching the Company, Clay worked for the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997. Prior to that Clay worked with the National Cancer Institute. Clay also served as a member of the Board of Director of the Alder BioPharmaceuticals.

Clay is an author and published over 70 publications. He also holds 15 patents.